www.neurologiepropraxi.cz / Neurol. praxi. 2023;24(5):346-352 / NEUROLOGIE PRO PRAXI 351 HLAVNÍ TÉMA Precizní neuroonkologie – realita a perspektivy LITERATURA 1. Appay R, Dehais C, Maurage C‑A, Alentorn A, et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH‑mutant gliomas. Neuro Oncol. 2019;21:1519-28. 2. Binabaj MM, Bahrami A, ShahidSales S, et al. The prognostic value of MGMT promoter methylation in glioblastoma: A meta‑analysis of clinical trials. J Cell Physiol. 2018;233:378-86. 3. Brat DJ, Aldape K, Colman H, et al. cIMPACT‑NOW update 5: recommended grading criteria and terminologies for IDH‑mutant astrocytomas. Acta Neuropathol. 2020;139:603-8. 4. Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus Procarbazine, CCNU, and Vincristine in Low‑Grade Glioma. N Engl J Med. 2016;374:1344-55. 5. Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long‑term results of RTOG 9402. J Clin Oncol. 2013;31:337-43. 6. Doroshow DB, Doroshow JH. Genomics and the History of Precision Oncology. Surg Oncol Clin N Am. 2020;29:35-49. 7. Doz F, van Tilburg CM, Geoerger B, et al. Efficacy and safety of larotrectinib in TRK fusion‑positive primary central nervous system tumors. Neuro Oncol. 2022;24:997-1007. 8. Ducray F, Sanson M, Chinot O, et al. KS02. 4. A Olaparib in Recurrent IDH‑mutant High‑Grade Glioma (OLAGLI). Neuro Oncol. 2021;23:ii4. 9. Federici L, Capelle L, Annereau M, et al. 5-Azacitidine in patients with IDH1/2-mutant recurrent glioma. Neuro Oncol. 2020;22:1226-8. 10. Gonzalez Castro LN, Wesseling P. The cIMPACT‑NOW updates and their significance to current neuro‑oncology practice. Neurooncol Pract. 2021;8:4-10. 11. Kaley T, Touat M, Subbiah V, et al. BRAF Inhibition in BRAFV600-Mutant Gliomas: Results From the VE‑BASKET Study. J Clin Oncol. 2018;36:3477-84. 12. Lassman AB, Sepúlveda‑Sánchez JM, et al. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Clin Cancer Res. 2022;28:2270-7. 13. Loriot Y, Schuler MH, Iyer G, et al. Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results. JCO. 2022;40:3007-3007. 14. Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:80320. 15. Louis DN, Perry A, Wesseling P, et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021;23:1231-51. 16. Machida Y, Nakagawa M, Matsunaga H, et al. A Potent Blood‑Brain Barrier‑Permeable Mutant IDH1 Inhibitor Suppresses the Growth of Glioblastoma with IDH1 Mutation in a Patient‑Derived Orthotopic Xenograft Model. Mol Cancer Ther. 2020;19:375-83. 17. Mellinghoff IK, Ellingson BM, Touat M, et al. Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. J Clin Oncol. 2020;38:3398-406. 18. Mellinghoff IK, Penas‑Prado M, Peters KB, et al. Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First‑in‑Human Phase I Trial. Clin Cancer Res. 2021;27:4491-9. 19. Nabors LB, Ammirati M, Bierman PJ, et al. Central nervous system cancers. J Natl Compr Canc Netw. 2013;11:1114-51. 20. Noushmehr H, Weisenberger DJ, Diefes K, et al. Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 2010;17:510-22. 21. Ostrom QT, Patil N, Cioffi G, et al. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. Neuro Oncol. 2020;22:iv1-96. 22. Platten M, Bunse L, Wick A, et al. A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. 2021;592:463-8. 23. Polívka J, Polívka J jr, Potužník P. Jak léčit nádory mozku v současnosti. Neurol. praxi. 2021;22:206-11. 24. Pusch S, Krausert S, Fischer V, et al. Pan‑mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo. Acta Neuropathol. 2017;133:629-44. 25. Rachdi A, Hernandez‑Tost H, et al. Recent advances in the diagnosis and the treatment of primary CNS lymphoma. Rev Neurol (Paris). 2023;179:481-9. 26. Reifenberger G, Wirsching H‑G, Knobbe‑Thomsen CB, Weller M. Advances in the molecular genetics of gliomas – implications for classification and therapy. Nat Rev Clin Oncol. 2017;14:434-52. 27. 14. Sahm F, Reuss D, Koelsche C, et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 2014;128:551-9. 28. Sepúlveda‑Sánchez JM, Vaz MÁ, Balañá C, et al. Phase II trial of dacomitinib, a pan‑human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Neuro Oncol. 2017;19:1522-31. 29. Smith HL, Wadhwani N, Horbinski C. Major Features of the 2021 WHO Classification of CNS Tumors. Neurotherapeutics. 2022;19:1691-704. 30. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-96. 31. Sulkowski PL, Corso CD, Robinson ND, et al. 2-Hydroxyglutarate produced by neomorphic IDH mutations suppresses homologous recombination and induces PARP inhibitor sensitivity. Sci Transl Med. 2017;9:eaal2463. 32. Thiessen B, Stewart C, Tsao M, et al. A phase I/II trial of GW572016 (lapatinib) in recurrent glioblastoma multiforme: clinical outcomes, pharmacokinetics and molecular correlation. Cancer Chemother Pharmacol. 2010;65:353-61. 33. Torre M, Vasudevaraja V, Serrano J, et al. Molecular and clinicopathologic features of gliomas harboring NTRK fusions. Acta Neuropathol Commun. 2020;8:107. 34. Turcan S, Fabius AWM, Borodovsky A, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine. Oncotarget. 2013;4:1729-36. 35. Unruh D, Zewde M, Buss A, et al. Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers. Sci Rep. 2019;9:8946. 36. van den Bent MJ, Brandes AA, Rampling R, et al. RandoSeznam zkratek 2-HG D-2-hydroxyglutarát MRI Magnetic resonance imaging ALK Anaplastic lymphoma kinase mTOR Mammalian target of rapamycin ATRX Alpha-thalassemia/mental retardation, X-linked MYB Myeloblastosis oncogene BRAF V-Raf murine sarcoma viral oncogene homolog B MYBL 1 Myb proto-oncogene like 1 CDK4/6 Cyclin-dependent kinase 4/6 NEC Not elsewhere classified CDKN2A/B Cyclin-dependent kinase inhibitor 2A/B NOS Not otherwise specified cIMPACT-Now Consortium to inform molecular and practical approaches to CNS tumor taxonomy – not official WHO NTRK Neurotrophic tyrosine receptor kinase CNS Centrální nervový systém OS Overall survival DNA Deoxyribonukleová kyselina PARP Poly(ADP-ribózo)polymeráza EANO European association of neuro-oncology PCV Prokarbazin, lomustin a vinkristin EGFR Epidermal growth factor receptor PFS Progression-free survival FGFR1 Fibroblast growh factor receptor 1 PR Partial response GBM Glioblastoma multiforme PTEN Phosphatase and tensin homolog G-CIMP Glioma CpG island methylator phenotype SD Stable disease H3F3A H3 histone family member 3A SHH Sonic hedgehog HR Homologní rekombinace TACC1/3 Transforming acidic coiled-coil-containing protein 1/3 IDH1/2 Izocitrát-dehydrogenáza 1/2 TERT Telomerase reverse transcriptase MAPK Mitogen activated protein kinase TP53 Tumor protein p53 MDM2 Murine double minute 2 WHO The World health organization MDM4 Murine double minute 4 WNT Wingless/integrated MGMT O-6-Methylguanin DNA methyltransferáza YAP1 Yes-associated protein 1 MHC Major histocompatibility complex ZFTA Zinc finger translocation associated
RkJQdWJsaXNoZXIy NDA4Mjc=